Fig. 1

Study design summary. Participants (n = 90) were screened, including 45 healthy controls (HC) and 45 patients with hypertension. Of these, 60 patients were included in the metabolomics study, 30 in the proteomics discovery phase, and 60 in the testing phase. Serum was collected for proteomics and metabolomics training.